Scholarlink

Purpuse of Review <p>Brain tumors in adolescents and young adults (AYAs), defined as individuals aged 15 to 39 years, represent a heterogeneous group with a broad prognostic spectrum and unique clinical challenges. As many AYAs experience prolonged survival, treatment decisions must balance efficacy with the risk of long-term side effects. This review outlines the initial diagnostic approach and highlights recent therapeutic advances.</p> Recent Findings <p>Advances in molecular diagnostics have refined tumor classification, enabled risk stratification, and supported the development of novel therapies. In selected tumors, targeted therapies are increasingly replacing conventional chemotherapy and radiation. Despite progress, treatment options for high-grade gliomas remain limited.</p> Summary <p>A deeper understanding of oncogenic pathways has led to promising targeted therapies. However, more studies are needed to define optimal treatment combinations, sequencing, and strategies to overcome resistance. Multidisciplinary care is essential to address both oncologic outcomes and survivorship.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Central Nervous System Tumors in Adolescents and Young Adults

  • 期刊论文

  • 发表日期：

    2025年8月12日

查看全文
  • Jaime Godoy-Santin,
  • Abitha Suthakaran,
  • Julie Bennett,
  • Mary Jane Lim-Fat

摘要

Purpuse of Review

Brain tumors in adolescents and young adults (AYAs), defined as individuals aged 15 to 39 years, represent a heterogeneous group with a broad prognostic spectrum and unique clinical challenges. As many AYAs experience prolonged survival, treatment decisions must balance efficacy with the risk of long-term side effects. This review outlines the initial diagnostic approach and highlights recent therapeutic advances.

Recent Findings

Advances in molecular diagnostics have refined tumor classification, enabled risk stratification, and supported the development of novel therapies. In selected tumors, targeted therapies are increasingly replacing conventional chemotherapy and radiation. Despite progress, treatment options for high-grade gliomas remain limited.

Summary

A deeper understanding of oncogenic pathways has led to promising targeted therapies. However, more studies are needed to define optimal treatment combinations, sequencing, and strategies to overcome resistance. Multidisciplinary care is essential to address both oncologic outcomes and survivorship.